SCHEMBL3465397

SCHEMBL3465397

CS(=O)(=O)c1cccc([CH]CC(N)=O)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
GAA P10253 2/20 0.40
HSD17B10 Q99714 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
LOX P28300 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.38
ADRA1D P25100 1/20 0.38
AKR1C3 P42330 4/20 0.37
AKR1C2 P52895 1/20 0.37
NQO2 P16083 1/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
VNN1 O95497 1/20 0.37
LMNA P02545 1/20 0.36
GRK6 P43250 1/20 0.36
NAMPT P43490 1/20 0.36
KIF11 P52732 1/20 0.36
GRM2 Q14416 1/20 0.36
GRM3 Q14832 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3465328 0.80 SMN1; SMN2 (0.41) ALDH1A1GAAHSD17B10SMN1; SMN2LOX
SCHEMBL3465179 0.80 DRD2 (0.42) ALDH1A1GAAHSD17B10SMN1; SMN2LOX
SCHEMBL3465078 0.77 CYP11B2 (0.37) LMNANAMPT
SCHEMBL30402657 0.76 CA12 (0.47) ALDH1A1SMN1; SMN2LOXLOXL2AKR1C3
SCHEMBL41941 0.76 CA12 (0.47) ALDH1A1SMN1; SMN2LOXLOXL2AKR1C3
SCHEMBL15157483 0.75 PARP1 (0.50) ALDH1A1AKR1C3
SCHEMBL3464491 0.74 AKR1C3 (0.35) ALDH1A1AKR1C3
SCHEMBL3465013 0.74 AKR1C3 (0.35) ALDH1A1HSD17B10AKR1C3LMNA
SCHEMBL3465180 0.74 CREBBP (0.40) ALDH1A1GAAHSD17B10SMN1; SMN2LOX
SCHEMBL2401016 0.73 ALDH1A1 (0.55) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346868-B1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2016-01-27 EP disclosed
US-8338610-B2 Pyridinyl compounds useful as intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-25 US disclosed
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-31 US disclosed
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists CCR1, CCR3, CCR4 ALDH1A1 523/4885GAA 3761/4885HSD17B10 3255/4885
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates CCR1, CCRL2, CCR4 ALDH1A1 268/4885GAA 4085/4885HSD17B10 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.